NASDAQ: AZRX

SEARCH

SIGN UP

Menu

Ongoing Clinical Trials

Pursuing Parallel Monotherapy and Combination Therapy Pathways

 Clinical Trial Indication #Patients Highlights
Phase 2 Dose Escalation Trial

Option2
ClinicalTrials.gov: NCT04375878 		 Cystic Fibrosis 30
  • Open label, crossover study comparing MS1819 to commercial PERTs
  • Study 2.2 mg/day and 4.4. mg/day using enteric capsules for gastric protection
Phase 2 Combination Therapy Dose Escalation Trial

Combination MS1819 PERT
ClinicalTrials.gov: NCT04302662		 Cystic Fibrosis
Severe EPI		 20-24
  • Add MS1819 to commercial PERT to improve patient control
  • Primary endpoint to increase CFA from baseline value of <80% on PERT alone